EUVIMEDEUVIMED entdecken
Crossref

Influenza Vaccine for 2023-2024

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1687a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1,2 Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanHumansAntiviral AgentsOseltamivirNeuraminidaseEnzyme Inhibitors

Stichwörter der Autor:innen

AfluriaFluLavalFluMistFluadFluarixFlublokFluceIvaxFluzoneFluzone High-DoseHeplisav-BRapivabRelenzaShingrixTamifluXofluza

Substanzen

Influenza VaccinesAntiviral AgentsOseltamivirNeuraminidaseEnzyme Inhibitors

Zitieren

APA

(2023). Influenza Vaccine for 2023-2024. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1687a

Vancouver

Influenza Vaccine for 2023-2024. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1687a

BibTeX
@article{euvimed2023,
  title = {Influenza Vaccine for 2023-2024},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1687a}
}
Kostenlos starten →